Currax Pharmaceuticals acquires Nalpropion Pharmaceuticals

Currax Pharmaceuticals, a specialty biopharma company having branded and generic drug businesses, has acquired Nalpropion Pharmaceuticals for an undisclosed price, as per the latest pharma acquisition news.

Through the acquisition, Currax gains the global rights to CONTRAVE (naltrexone HCl and bupropion HCl extended release), a prescribed weight-loss drug in the US, which has patent protection till 2034.

CONTRAVE functions in two parts of the brain to enable some adults regulate their eating, thereby helping in sustained weight loss. It was approved by FDA in late 2014.

The weight loss drug is indicated to be used by patients having a body mass index (BMI) of 30kg/m2 or greater (obese), or adults having a BMI of 27 kg/m2 or greater (overweight) with at least on weight-related medical issues like high blood pressure, high cholesterol, or type 2 diabetes, for losing weight and maintaining their weight loss.

Commenting on Currax acquisition of Nalpropion, George Hampton – CEO of Currax Pharmaceuticals, said: “It is exciting to announce our second acquisition in as many days. This acquisition bolsters our Branded portfolio and demonstrates that we are successfully executing on our business strategy to acquire clinically differentiated medicines with high potential for growth and extended IP life.”

Currax Pharmaceuticals is engaged in acquiring and marketing prescription drugs in the US. The specialty pharmaceutical business distributes a variety of branded and generic pharma products such as Silenor, Treximet, Zohydro ER with BeadTek, the authorized generic of Treximet, and ONZETRA Xsail.